Graft Versus Host Disease (GVHD) Market Size

Graft Versus Host Disease Market Size

Graft Versus Host Disease Market size was valued at USD 2.5 billion in 2023 and is expected to reach USD 5.1 billion by 2032 growing at a CAGR of 8.1% over the analysis period, due to the increasing prevalence of hematological disorders and malignancies necessitating hematopoietic stem cell transplantation (HSCT).

To get key market trends

  Download Free Sample

The global increase in HSCT procedures has correspondingly driven up the incidence of GVHD, necessitating the need for effective therapeutic solutions to address this complication. Despite considerable advancements in donor selection, conditioning regimens, and supportive care, GVHD remains prevalent, thereby impacting approximately 30% to 50% of patients undergoing allogeneic HCT. A study published in (NCBI) stated that 42% of U.S. patients developed cGVHD within three years post-allogenic HSCT, often preceded by acute GVHD. This surge in the patient population affected by GVHD fuelled the development and adoption of novel treatments, thereby contributing to market expansion.

GVHD arises following hematopoietic stem cell or bone marrow transplantation, characterized by the donor's immune cells (graft) attacking the recipient's tissues (host). The immune reaction triggers inflammation and organ damage, affecting vital areas such as the skin, liver, gastrointestinal tract, and lungs. Also, the GVHD poses a substantial hurdle in transplantation, influencing patient well-being and necessitating specialized therapies to address its manifestations and complexities.